'Evolution-Proofing' Antibacterials

Evolution, Medicine and Public Health

Volumn 2014, Issue 1, 2014, Pages 134-135

  Ross Gillespie, Adin ^a   Kümmerli, Rolf ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL INFECTION; BACTERIAL MUTATION; BACTERIAL VIRULENCE; BACTERIUM MUTANT; DRUG EFFICACY; NATURAL SELECTION; NONHUMAN; PRIORITY JOURNAL;

EID: 85043619050     PISSN: None     EISSN: 20506201     Source Type: Journal    
DOI: 10.1093/emph/eou020     Document Type: Article

References (9)

1. Burnet M. Natural History of Infectious Disease, 1962. Cambridge University Press.
2. Clatworthy AE, Pierson E and Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 2007;3: 541-8.
3. WHO.Antimicrobial Resistance: Global Reporton Surveillance, 2014.
4. Allen RC, Popat R, Diggle SP et al. Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol 2014;12:300-8.
5. Fernández L and Hancock REW. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev 2012;25:661-81.
6. Ross-Gillespie A, Weigert M, Brown SP et al. Gallium-mediated siderophore quenching as an evolutionarily robust antibacterial treatment. Evol Med Pub Health 2014;2:18-29.
7. Tamma PD, Cosgrove SE, Maragakis LL et al. Combination therapy for treatment of infections with gram-negative bacteria. Clin Rev Microbiol 2012;25:450-70.
8. Travier L, Rendueles O, Ferriéres L et al. Escherichia coli resistance to nonbiocidal antibiofilm polysaccharides is rare and mediated by multiple mutations leading to surface physicochemical modifications. Antimicrob Agents Chemother 2013;57:3960-68.
9. Lu C, Maurer CK, Kirsch B et al. Overcoming the unexpected functional inversion of a PqsR antagonist in Pseudomonas aeruginosa: an in vivo potent antivirulence agent targeting pqs quorum sensing. Angew Chem Int Ed 2014;53: 1109-12.